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Abstract
Tumor-associated stroma is typified by a persistent, non-resolving inflammatory response that
enhances tumor angiogenesis, growth and metastasis. Inflammation in tumors is instigated by
heterotypic interactions between malignant tumor cells, vascular endothelium, fibroblasts, immune
and inflammatory cells. We found that tumor-associated adipocytes also contribute to
inflammation. We have analyzed peritumoral adipose tissue in a syngeneic mouse melanoma
model. Compared to control adipose tissue, adipose tissue juxtaposed to implanted tumors
exhibited reduced adipocyte size, extensive fibrosis, increased angiogenesis and a dense
macrophage infiltrate. A mouse cytokine protein array revealed up-regulation of inflammatory
mediators including IL-6, CXCL1, MCP-1, MIP-2 and TIMP-1 in peritumoral versus counterpart
adipose tissues. CD11b+ macrophages contributed strongly to the inflammatory activity. These
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macrophages were isolated from peritumoral adipose tissue and found to overexpress ARG1,
NOS2, CD301, CD163, MCP-1 and VEGF, which are indicative of both M1 and M2 polarization.
Tumors implanted at a site distant from subcutaneous, anterior adipose tissue were strongly
growth-delayed, had fewer blood vessels and were less populated by CD11b+ macrophages. In
contrast to normal adipose tissue, micro-dissected peritumoral adipose tissue explants launched
numerous vascular sprouts when cultured in an ex vivo model. Thus, inflamed tumor-associated
adipose tissue fuels the growth of malignant cells by acting as a proximate source for vascular
endothelium and activated pro-inflammatory cells, in particular macrophages.
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Introduction
Both tumors and healing wounds elicit stromal reactions that are characterized by
mobilization of pro-inflammatory cells, matrix remodeling, fibroblast activation and
angiogenesis [1, 2]. The stromal reaction in wounds is a tightly controlled, physiological
process necessary for healing, whereas in tumors, a “smoldering” inflammatory response
promotes the survival of malignant cells and stimulates pathophysiological angiogenesis [3].
Heterotypic interactions between malignant cells and the underlying stromal cells are a
driving force during progression [4]. Thus, changes in the stroma or nearby tissue may
accompany tumor progression and actively contribute to the survival and propagation of
malignant cells.
Among the tumor stromal cells are endothelial cells, pericytes, smooth muscle cells,
fibroblasts, myofibroblasts and adipocytes. Infiltrating immune cells are represented by
lymphocytes, neutrophils and other granulocytes, as well as antigen presenting cells such as
dendritic cells and macrophages [1]. Tumor associated macrophages (TAMs) are well-
studied for their role in creating a permissive micro-environment for tumor growth [5].
Tumors have a higher number of macrophages when compared to normal tissues [6, 7].
TAMs are derived from circulating monocytes in the blood, which respond to tumor- and
stromal-derived chemo-attractants including MCP-1 (CCL2) and SDF-1 (CXCL12) [8-10].
TAMs and other pro-inflammatory cells may be trapped in the tumor microenvironment at
the periphery of inflamed tumor blood vessels, associated with fibrosis or localized near
areas of necrosis and hypoxia [8, 10-12].
Adipocytes are perhaps the least studied stromal cells in tumors, despite the fact that in some
cancer types, particularly breast cancers, malignant cells are in direct contact with the
adipocytes [13, 14]. Adipose tissue (AT) is composed of lipid-filled adipocytes and the
stromal vascular fraction (SVF). Resident monocytes/macrophages represent a large
proportion of the SVF. Macrophages are remarkably plastic cells and can assume multiple
phenotypes. Classically activated M1 macrophages, associated with microbial killing, are
tumor-suppressive and may lyse tumor cells and stimulate adaptive immunity [15].
Alternatively activated M2 macrophages are associated with tissue remodeling and
angiogenesis [15, 16]. It is suggested that TAMs are M2-polarized although they may switch
their phenotype depending on tumor grade or stage [17, 18]. Moreover, some TAMs may
exhibit a “mixed” phenotype and express pro-inflammatory (e.g. NOS2) and
immunosuppressive (e.g. ARG1) factors simultaneously [19, 20].
Wagner et al. Page 2
Angiogenesis. Author manuscript; available in PMC 2013 April 08.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Excess adiposity (obesity) is associated with an increased cancer risk attributed to higher
levels of circulating pro-inflammatory factors and tissue damage caused by the activity of
pro-inflammatory cells [21]. Adipocyte-derived trophic factors (adipokines) may also
stimulate the growth of tumor cells directly [22]. While AT-associated macrophages
(ATMs) have been well-characterized in lean versus obese adipose depots [23-26], tumor-
associated AT has not been studied in this regard. We hypothesized that peritumoral AT
may serve as a depot for activated, tumor-infiltrating macrophages which could support
tumor growth, possibly by stimulating neovascularization and exacerbating inflammation.
Collectively our data demonstrate that (1) tumor cells alter an adjacent AT depot by
inducing fibrosis, angiogenesis and inflammation (2) macrophages isolated from peritumoral
adipose tissue display characteristics of both M1 and M2 phenotypes (3) inflamed, highly
vascularized and angiogenic peritumoral AT may support tumor expansion at the periphery.
These findings may be of particular relevance for tumors which grow directly within AT
(e.g. breast tumors) or in metastases to lymph nodes which are typically ensheathed by
adipocytes.
Materials and methods
Mice
7–10 week-old male C57BL/6 mice were used in all experiments and were purchased from
The Jackson Laboratory. All animal experiments were performed with the approval of the
animal use and care committee at The Children’s Hospital, Boston. Mice were euthanized by
CO2 inhalation.
Cell lines
B16F10, Lewis Lung Carcinoma (LLC) and MS1 endothelial cells were obtained from the
American Type Culture Collection (ATCC). Tumor cells were grown at 37 °C in 5 % CO2
in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with non-essential amino
acids, 10 % fetal calf serum, 100U/ml penicillin, 100 μg/ml of streptomycin and 400 μM L-
glutamine (Cambrex, Lonza, Switzerland). Endothelial cells were grown at 37 °C in 5 %
CO2 in DMEM supplemented with non-essential amino acids, 5 % fetal calf serum, 100U/
ml penicillin, 100 μg/ml of streptomycin and 400 μM L-glutamine.
Tumor cell implantation, peritumoral and control adipose tissue collection
For tumor growth studies, cells (1 × 106) were resuspended in 100 μl Matrigel (BD
Biosciences) and injected into the anterior, subcutaneous AT depot or along the dorsal
midline in C57BL6 mice. The use of matrigel was necessary to prevent tumor cells from
spreading beyond the injection site. Tumor growth was measured at regular intervals using
calipers. Tumor volume was calculated using the formula a2*b*0.52 where a and b are the
shorter and longer diameter of the tumors, respectively. When tumors exceeded 2 cm in
diameter, animals were euthanized. For AT studies, peritu-moral AT was collected by
microdissection under a stereoscopic microscope. Control AT from the counterpart depot
was collected from age- and sex-matched animals.
Adipose tissue incubation and measurement of lipolysis
Lipolysis was measured from control and peritumoral AT explants normalized to 0.2 g.
Explants were washed in sterile Hank’s balanced salt solution (HBSS) to remove lipid and
cell fragments from cut surfaces and then incubated in DMEM supplemented with non-
essential amino acids, 10 % fetal calf serum, 100 U/ml penicillin, 100 μg/ml of streptomycin
and 400 μM L-glutamine overnight at 37 °C in 5 % CO2. Hoechst 33258 nuclear staining
was performed in order to distinguish lipid droplets from adipocytes. Lipid droplet size was
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measured using the ImageJ software package available for free from the National Institutes
of Health (NIH).
Morphometric analysis of adipocytes
Morphometric data were obtained from >1,000 adipocytes from three 7 μM sections from
three different mice per group. Adipocyte volume was determined using NIS-elements AR
software from Nikon.
Histochemistry
Oil red O staining—Frozen AT was sectioned in 7 μm slices and mounted on slides. The
slides were fixed for 10 min in a 10 % solution of formaldehyde in aqueous phosphate
buffer and washed four times with water. This was followed by incubation in 60 %
isopropanol for 5 min. Tissue was air-dried and later stained using Oil-Red-O solution for 15
min. After rinsing with isopropanol to remove the Oil-Red-O solution and counterstaining
with Mayer’s hematoxylin solution for 2 min, the slides were mounted and observed under
light microscopy. To measure neutral triglycerides, control and peritumoral AT were
normalized to 0.2 g, minced and stained with Oil Red O according to modified procedure of
Janderová et al. [27]. In brief, AT was fixed in a 10 % solution of formaldehyde in aqueous
phosphate buffer for 1 h, washed with 60 % isopropanol and then stained with Oil-Red-O
solution (in 60 % isopropanol) for 10 min. Tissue was then repeatedly washed with water
and destained in 100 % isopropanol for 10 min. The optical density of the isopropanol
solution was measured at 500 nm.
Masson’s trichrome staining—Paraffin-embedded AT sections were deparafinized and
hydrated in xylene and ethanol and re-fixed for 1 h in Bouin’s solution. After incubation in
Harris Hematoxylin solution, the slides were stained with Biebrich Scarlet-Acid Fuchsin,
Phosphomolybdic–phosphotungstic acid solution and Aniline Blue and dehydrated in
ethanol and xylene. Extensive washes were done between each staining. The collagen fibers
were stained blue, the nuclei were stained black. Cytoplasm, muscle and keratin were
stained red.
Picrosirius red staining—Paraffin embedded AT sections were deparafinized and
hydrated in xylene and ethanol. After incubation in Harris Hematoxylin solution, the slides
were stained with Picrosirius Red solution and dehydrated in ethanol and xylene. Washes in
two changes of acidified water were done after Picrosirius Red staining. The collagen fibers
were stained orange when examined using polarized light microscopy.
Immunohistochemistry and immunofluorescence
Paraffin embedded and frozen sections were used for immunohistochemistry and
immunofluorescence. Primary antibodies were as follows: rabbit anti-CD45 (1:500; Abcam),
goat anti-CD31 (1:100; Santa Cruz Biotechnology), rabbit anti-LYVE-1 (1:100; Abcam), rat
anti-CD301 (1:50; AbD Serotec), rabbit anti-CD163 (1:100; Santa Cruz Biotechnology),
rabbit anti-CD11b (1:200; Abcam), rabbit anti-IL6 (1:100; Abcam), rabbit anti-Ki-67
(1:100; Ab-cam), rat anti-CD31 (1:100; Abcam). Secondary antibodies were as follows:
Alexa Fluor 488 anti-rat IgG (1:200; Invitrogen). Cy2 anti-rat IgG (1:200, Jackson
ImmunoResearch), Cy3 anti-rabbit IgG (1:200, Jackson Immuno Research). Vectastain Elite
ABC system kits were used for IHC (Vector Laboratories).
Flow cytometry and FACS
Freshly harvested samples of control and peritumoral AT were incubated with a mixture of
collagenase Type-2 (1 mg/ml)/dispase (2.5 μg/ml) and DNase (1 mg/ml) for 1 h at 37 °C
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with continuous rotation. The dissociated tissue was fractionated by sedimentation
centrifugation at 186 g for 10 min and the pelleted stromal vascular fraction was filtered
through a 70 μm mesh cell strainer (BD Bioscience) to remove debris. Contaminating
erythrocytes were lysed using red blood cell lysis buffer (BD Pharmingen). Single cell
suspensions were prepared for flow cytometry by suspension in FACS buffer (0.5 % w/v
BSA, 0.5 M EDTA in sterile PBS). Cells were blocked with Fc-blocking reagent (Miltenyi
Biotec) to prevent nonspecific binding, labeled with appropriate antibodies for 30 min at 4
°C and then acquired on a BD FACSCalibur (CellQuest Pro software; BD Bioscience), and
analyzed using FlowJo software (Tree Star, Inc.).
Preparation of conditioned medium
SF macrophage-conditioned medium was prepared from Cd11b+ cells isolated from control
or peritumoral AT by FACS. Twenty-four hours after medium replacement conditioned
medium was aspirated and filtered through a 0.22 μm membrane (Millipore) to remove any
cell debris and stored at −80 °C. The whole conditioned medium was chosen to maximize
the chance of detecting a cell response to soluble factors.
Endothelial cell proliferation assay
Serum-starved MS1 cells were seeded into a 96-well microtiter plate at a final density of 2.5
× 103 cells/well in 100 μl of SF macrophage-conditioned medium or SF medium
supplemented with different concentrations of mIL6 (R&D Systems). After 24 h of
incubation, each well was treated with 20 μl of a solution comprising 1.9 mg/mL of MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 tetrazolium,
inner salt; MTS] in phosphate-buffered saline (PBS) pH 6.0. The plate was then incubated
for an additional 1 h. The absorbance of the soluble formazan salt was measured against a
tetrazolium standard, MTS solution.
Ex vivo angiogenesis assay
Freshly harvested samples of mouse control and peritumoral AT were placed in sterile
Endothelial Basal Medium (EBM-2) (Lonza) without supplements. The tissue was cut into 1
mm3 pieces and embedded in an individual well of a 96-well plate containing 50 μl of
growth factor–depleted Matrigel (BD Discovery Labware). The size of each piece varied in
the range of 1 ± 0.5 mm3. Wells were filled with 200 μl of EBM-2 devoid of growth factors,
and half of the media was replaced every second day. After 7 days, the percentage of
explants launching capillary branches from control and tumor-bearing mice (n = 4 per
group) out of the total number of explants (n = 16 per group) was recorded.
Cytokine protein array
Whole AT protein lysates were incubated with pre-coated cytokine array membranes
(Proteome Profiler Arrays, R&D Systems). Densitometric analysis of the dot blots, showing
the mean pixel density was performed using ImageJ software. Loading variability between
separate membranes was controlled for by densitometry of the positive control spots,
followed by normalizing the density of each cytokine to the mean density of positive
controls.
RT-PCR
Cd11b+ cells were isolated by FACS and total cellular RNA was extracted using the RNeasy
Kit according to the manufacturer’s protocol (Qiagen). RNA purity and quantity was
measured spectrophotometrically. Two hundred and fifty ng of RNA was subjected to
reverse transcription by standard methods. 1.5 μl of cDNA was then used in a 25 μl PCR
reaction containing a 250 nM concentration of each primer, 0.5 μl of dNTPs (10 mM stock),
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2.5 μl of 10 × PCR buffer with MgCl2 (Invitrogen), and 0.5 μl of Taq DNA polymerase
(Roche).
Statistics
In all experiments, the statistical significance was analyzed by unpaired Student’s t test,
using Prism software (GraphPad Inc.). The value of p < 0.05 was considered statistically
significant.
Results
Peritumoral AT is characterized by reduced adipocyte size, lipolysis and reduced lipid
accumulation in vivo
To characterize peritumoral AT, B16F10 melanoma cells were implanted into one of the
anterior subcutaneous AT depots in immunocompetent C57BL6/J mice. At 14 days post
implantation, peritumoral AT was carefully microdissected away from the surrounding
tumor mass and subcutaneous connective tissue. Gross examination of peritumoral AT
revealed an inflamed, dark reddish-white mass compared to control AT from a
corresponding depot (Fig. 1A, a). Peritumoral AT weighed almost twice as much as control
AT (Fig. 1A, b) although there was no difference in body weight between control and
tumor-bearing mice (Fig. 1A, c). Under microscopic examination of H&E-stained sections,
peritumoral adipocytes were smaller than their normal counterparts and typified by areas of
dense collagen deposition (as judged by eosin stain) (Fig. 1A, d). Adipocytes in breast
tissues from autochthonous tumors in C3-Tag mice were also smaller and more sparse
compared to normal breast tissues (Fig. 1A, e). When measured using NIS-elements AR
software, adipocytes from peritumoral AT were approximately 30 % smaller than adipocytes
from control AT. The median size was 666 μm2 (n = 1,369) for peritumoral AT adipocytes
and 1,032 μm2 (n = 1,358) for control AT adipocytes (Fig. 1b, a–b). The mean sizes were
824.5 ± 16.29 μm2 for adipocytes from peritumoral AT and 1,179 ± 17.68 μm2 for
adipocytes from control AT (p <0.0001) (Fig. 1B, c). There was no difference in the total
number of adipocytes between control and peritumoral AT (data not shown).
Next, freshly isolated adipocytes from control versus peritumoral AT were placed into
culture. After an overnight incubation, we observed increased numbers of lipid droplets
from peritumoral AT that were on average 2-5 fold larger than those from control AT (lipid
droplet diameter was measured using ImageJ software, n = 100) (Fig. 1B, d–e). Hoechst
33258 nuclear staining allowed distinguishing lipid droplets from true adipocytes (not
shown). In vivo, when normalized as a per tissue mass basis, there was a 17 % decrease in
lipid accumulation in peritumoral versus control AT determined by extracting Oil-Red-O
and measuring the absorbance at 500 nm according to modified procedure of Janderová et
al. [27] (Fig. 1C, a–b). Taken together, these results suggest that peritumoral AT is
characterized by smaller adipocytes, lipolysis and decreased lipid accumulation.
Peritumoral AT is characterized by extensive fibrosis and greater blood vessel density
We hypothesized that decreased lipid accumulation in peritumoral AT might be explained
by increased collagen content, fibrosis and loss of adipocyte function (as judged by eosin
and Oil-Red-O staining). Masson’s and Picrosirius Red stains were used to identify
collagen. When measured by NIS-elements AR software, a 2-3 fold increase in collagen
content was observed in peritumoral versus control AT using Masson’s trichrome (Figs. 2A,
B, a). Furthermore, increased numbers of vessels filled with red blood cells were observed
within peritumoral AT (Figs. 2A, B, b–c). After confirming peritumoral AT fibrosis using
Picrosirius Red (Fig. 2C, a–b), we performed immunohistochemical staining using CD31 as
a pan-EC marker. The results confirmed an increased number of blood vessels in
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peritumoral AT when compared to control AT (Fig. 2C, c). Notably, the majority of blood
vessels were localized within or adjacent to fibrotic areas as shown in Fig. 2A above.
Peritumoral AT is enriched with macrophages that express the C-type lectin 10A
(CLEC10A/CD301), a marker of M2 polarization
Fibrotic areas within peritumoral AT were infiltrated by what appeared to be mononuclear
cells. To define the cellular component of these fibrotic areas, control and peritumoral AT
were examined using immunohistochemistry. This analysis revealed a massive infiltration of
CD45-positive hematopoietic cells in peritumoral AT (Fig. 3A). Since macrophages, for
example in obese subjects, can constitute up to 40 % of the cell population within AT [24,
28], we quantitatively and qualitatively characterized macrophages in control and
peritumoral AT. Flow cytometric analysis using CD11b and CD301 antibodies was
performed. When normalized to 0.2 g of tissue, the number of both CD11b+/CD301−
(17,078 ± 4,403 cells/depot vs. 1,339 ± 222 cells/depot, n = 3, p < 0.05) and CD11b+/
CD301+ (112,128 ± 6,510 cells/depot vs. 1,606 ± 93 cells/depot, n = 3, p <0.0001) cells was
greater in peritumoral AT compared to control AT (Fig. 3B). Within control AT, there was
no statistically significant difference between CD11b+/CD301− and CD11b+/CD301+ cells,
whereas within peritumoral AT there was a 6.6-fold increase in the number of CD11b+/
CD301+ cells (Fig. 3B, graph). Immunohistochemical analysis using antibodies against
CD301 and CD163 (a scavenger receptor expressed by monocytes/macrophages) revealed
that the majority of positively stained cells were found mainly within fibrotic and highly
vascularized areas (Fig. 3C, a–c), suggesting that the formation of blood vessels could be
related to the infiltration of macrophages.
Peritumoral AT is characterized by an up-regulation of pro-inflammatory cytokines and
chemokines
Next, we characterized the cytokine expression signature of peritumoral versus control AT
using proteome profiler arrays specific for mouse cytokines. Of 40 total cytokines, the
majority were unchanged in peritumoral versus control AT. However, IL-6, CXCL1,
MCP-1, MIP-2, and TIMP-1 were expressed 2-6 fold higher in peritumoral AT compared to
control AT (Fig. 4A, a–b). On the other hand, IL-16 expression was about 2 fold lower in
peritumoral versus control AT. Because IL-6 showed the most striking difference in
peritumoral versus control AT we further characterized IL-6 expression using
immunohistochemistry. The results showed intense IL-6 expression in peritumoral AT (Fig.
4B, a). IL-6 appeared to co-localize with vascular and mononuclear cells. Colocalization of
IL-6 with CD11b, confirmed IL-6 expression in monocytes/macrophages (Fig. 4B, b). We
hypothesized that macrophage or vascular-derived IL-6 might stimulate proliferation of
vascular endothelial cells [8, 11, 29]. To test this possibility, we examined mouse
endothelial cell proliferation under IL-6 stimulation in low serum conditions. Quantification
of endothelial cell numbers showed a 2-2.5 fold increase in proliferation in IL-6-treated
versus untreated controls (Fig. 4B, c).
Peritumoral AT-associated macrophages are closely aligned with vascular structures and
they express markers of both M1 and M2 polarization
Immunohistochemical analysis showed that CD11b+ macrophages within peritumoral AT
were typically found surrounding blood vessels, or tethered to the blood vessel wall (Fig.
5A, a). Vascular cells within peritumoral AT were also Ki-67 positive suggesting that these
cells were proliferating (Fig. 5A, a). Ki-67 staining could be co-localized with the
endothelial cell marker CD31 (data not shown). Next CD11b+ macrophages from control
AT, peritumoral AT and tumors (TAMs) were sorted by FACS and analyzed for markers of
M1- and M2-polarization. RT-PCR showed appropriate sorting of the macrophages based on
expression of F4/80 (Fig. 5A, b). Both TAMs and peritumoral AT macrophages expressed
Wagner et al. Page 7
Angiogenesis. Author manuscript; available in PMC 2013 April 08.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the M2 macrophage markers ARG1 and VEGFA. The M1 macrophage markers NOS2 and
MCP-1 were also expressed by TAMs and macrophages from peritumoral AT (Fig. 5A, b).
These results suggest that macrophages from peritumoral AT are qualitatively different from
control AT and closely resemble TAMs and that either two distinct populations of
macrophages are present or that M1 and M2 markers are co-expressed in a single
population.
To gain insight into the angiogenic potential of peritumoral AT versus control AT we
performed a modified ex vivo AT angiogenesis assay originally described by Gealekman et
al. [30]. One week after AT explants were embedded in growth factor reduced matrigel,
capillary sprouts emerged from peritumoral, but not control AT explants. (Fig. 5B, a–b).
Immunohistochemical analysis of tissue explants revealed that CD11b+ cells persisted
within peritumoral AT during the course of the experiment (7 days) (Fig. 5C, a). We
speculated that the increased angiogenic capacity of peritumoral AT was related to the
presence of activated macrophages. To examine this possibility, we collected conditioned
medium (CM) from freshly isolated control or peritumoral AT Cd11b+ cells. CM from
peritumoral AT macrophages alone was sufficient to stimulate EC proliferation above
controls by 1.5 fold (Fig. 5C, b).
Tumors implanted at a site distant from flank white adipose tissue are growth delayed,
less angiogenic and contain fewer monocytes/macrophages
In mice, two white AT depots are located along the scapula and near the hind limbs. We
took advantage of the anatomic position of these AT depots to examine differences in tumor
growth and neovascularization when tumors were implanted directly within an AT depot, or
in site distant from one of these depots. B16F10 melanoma cells or Lewis Lung Carcinoma
(LLC) cells were implanted into one of the anterior subcutaneous AT depots (fat pad) or into
the dorsal midline (no fat pad) of the same mouse. There was a striking difference in tumor
appearance depending on where tumor cells were implanted (Fig. 6A, a). B16F10 tumors
implanted along the midline were pale in appearance and appeared less vascular. Tumor
cells implanted in AT grew more rapidly, were more vascularized and weighed 2-4 fold
more than those implanted along the dorsal midline for both B16F10 (Fig. 6A, b, c) and
LLC (Fig. 6A, d, e). Next, we assessed the tumor vasculature in tumors implanted in the two
different anatomical sites. Immunohistochemical analysis of CD31 expression showed a 3
fold increase blood vessel density and a 4 fold increase in blood vessel area in tumors
growing in AT compared to those growing along the dorsal midline (Fig. 6B, a–c).
Furthermore, tumors growing within AT were replete with CD11b+ monocytic cells, in
contrast to those growing along the dorsal midline (Fig. 6B, d). Taken together, these results
suggest that tumors growing within or near AT are more vascular, they harbor more pro-
inflammatory cells and they have a growth advantage compared to those tumors grown
without a nearby AT depot.
Discussion
Although normal cells and tissue architecture may impede cancer growth and underlie the
persistence of occult tumors, occasionally, tissue homeostasis is disrupted and the scales are
tipped towards a microenvironment that favors tumor progression [31]. For example, the
“angiogenic switch” whereby tumors acquire the ability to stimulate neovascularization
greatly enables tumor expansion [32, 33]. Similarly, tumor-associated inflammation, which
could be fueled by the activity of oncogenes or associated with tissue damage and hypoxia,
creates a permissive microenvironment favorable for tumor growth. While malignant cells
are primarily dependent on cell-autonomous mutations that result in their immortality [33],
three-dimensional growth beyond a few millimeters requires collaboration with stromal cells
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which provide additional growth and survival signals, cellular scaffolds and blood vessels
[34-36].
It is well established that stromal cells in tumors do not resemble their counterparts in
normal tissue. There are multiple reports of morphological, cytogenetic, and epigenetic
alterations in the stroma or tissue located at the periphery of various malignancies [1, 37,
38]. These studies have primarily focused on tumor-associated fibroblasts or mesenchymal-
like cells which, along with pro-inflammatory cells, comprise perhaps the largest proportion
of the stromal compartment. Spurred by the observation that adipose tissue located adjacent
to tumors implanted under the skin in mice was inflamed, fibrotic and replete with pro-
inflammatory cells, we have characterized tumor-associated AT using
immunohistochemistry, high-throuput proteome arrays and gene expression analysis of
freshly isolated adipocytes and AT-associated macrophages.
Adipocytes from peritumoral AT were reduced in size and lipid content when compared to
their normal counterparts suggestive of lipolysis and modification of adipocyte basement
membranes [13]. Similar to what occurs in tumor blood vessels [39, 40], biomechanical
forces created by the growing mass of tumor cells may “squeeze” the tumor-associated
adipocytes resulting in distortion of cellular membranes and rupture. Adipocyte membranes
are fragile and vulnerable to mechanical pressure; thus, spillage of lipids and triglycerides
from damaged adipocytes could trigger macrophage activation and inflammation [26].
Nieman et al. demonstrated that adipocyte/cancer cell co-culture leads to the transfer of
lipids from adipocytes to cancer cells, which accelerates tumor cell proliferation in vitro and
in vivo [41]. Additionally, adipocytes undergo lipolysis whereas cancer cells undergo beta-
oxidation, suggesting that adipocytes act as an energy source by providing free fatty acids
(FFA) needed for tumor growth [41].
It is suggested that adipocytes are diminished during early steps of tumor progression; thus,
histological images of tumor biopsies frequently contain few adipocytes [13]. Accounting
for this feature, tumor-associated adipocytes, after undergoing a process of de-
differentiation, may form tumor-associated fibroblasts [42, 43]. Adipocyte de-differentiation
into mesenchymal-like cells could therefore represent one source of fibrosis and collagen
deposition we observed in peritumoral versus control AT depots. Endothelial cells
undergoing endothelial-to-mesenchymal transition may also give rise to fibroblast-like cells
in tumors [44] and in sites of inflammation [45]. There are clear links between fibrosis and
inflammation, especially in the kidney, gut and in tumors [46]. For example, obstructive
nephropathy has a major inflammatory component, characterized by increased expression of
pro-inflammatory cytokines including TNF-α and IL-1 and increased infiltration of
macrophages and lymphocytes [47]. Recently, granulin+ neutrophils were shown to
stimulate fibrosis and formation of desmoplastic stroma in breast cancer [48]. Macrophages
both stimulate and resolve fibrosis [49]. Macrophage depletion during the recovery phase in
a reversible model of liver injury led to a failure of matrix degradation [49]. Wound healing
in PU.1-null mice, which essentially lack macrophages, occurs in the absence of fibrosis [50,
51]. In MCP-1(−/−) mice, which lack monocytes, tissue repair is characterized by delayed
angiogenesis and reduced collagen synthesis [52]. TIMP-1 is suggested to play a role in
fibrosis and collagen deposition because it inhibits the activity of macrophage-derived
matrix metalloproteinases (MMPs) including MMP2 and MMP9 [53]. We found that
TIMP-1 expression was two-fold higher in peritumoral AT compared to counterpart AT.
Peritumoral AT was also highly vascularized, and the majority of blood vessels were
localized within fibrotic areas [54]. One possibility is that the overproduction of TIMP-1 in
peritumoral AT blocks the activity of MMPs, which enables fibrosis and angiogenesis.
Interestingly, Liu et al. demonstrated that fibroblast-derived TIMP-1 enhances the tube-
forming abilities of endothelial cells in an in vitro model [55].
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Macrophages patrol most tissues throughout the body. Their numbers increase during
inflammation, wounding and malignancy through both increased mobilization and
proliferation of resident macrophages [50, 56]. Peritumoral AT harbored greater numbers of
monocytes/macrophages compared to counterpart AT. The source for these macrophages
may be the bone marrow, spleen or proliferation of resident AT-associated macrophages.
Jenkins et al. found that macrophage proliferation, rather than recruitment, was the principle
source of M2-polarized macrophages in sites of inflammation related to pathogen infection
[57]. We found a large number of Ki-67+ macrophages in peritumoral AT consistent with
proliferation; however, we cannot rule out the possibility that new macrophages in
peritumoral AT are derived from multiple sources, including the circulation. Indeed, we
found increased expression of monocyte/macrophage chemotactic factors including CXCL1,
macrophage-inflammatory protein-2 (MIP-2) and monocyte chemotactic protein-1 (MCP-1)
in peritumoral AT. As shown by Tanimoto et al., antibodies against CXCR2, a receptor for
CXCL1 and MIP-2, almost completely inhibited the infiltration of neutrophils and
monocytes/macrophages in an inflammation model induced by injection of necrotic
leukemic P388 cells into the peritumoral cavity [58]. On the other hand, administration of an
antibody against MCP-1 alone inhibited the infiltration of monocytes/macrophages but not
neutrophils [58]. These data indicate that necrotic cells alone induce inflammation and
suggest that CXCL1, MIP-2 and MCP-1 play important roles in the infiltration of
inflammatory cells during this process. Moreover, Armstrong et al. demonstrated that
CXCL1 and MIP-2 are expressed by different cell types at different times following tissue
injury. Fibroblasts and endothelial cells are the main source of CXCL1 in the skin six hours
after injury whereas later production of MIP-2 is confined to inflammatory cells including
neutrophils and monocytes/macrophages [59].
In wounds, macrophages operate as phagocytes, which scavenge matrix and cellular debris
and initiate revascularization and repair of the tissue. Macrophages from peritumoral AT
were typified as M2-like by expression of CD301 and CD163, which are scavenger
receptors. However, further characterization revealed expression of NOS2 and arginase. The
NOS2 pathway predominates in M1-polarized macrophages and competes with arginase for
the same substrate, L-arginine. In M1-activated macrophages, L-arginine is metabolized to
nitric oxide by NOS2. On the other hand, in M2 macrophages L-arginine is metabolized by
arginase to urea and L-ornithine, precursors of polyamines and collagen involved in tissue
remodeling. It has been shown that NOS2 expression precedes arginase expression at wound
sites [61]. Early inflammatory responses are characterized by increased NOS2 expression
where nitrogen intermediates are involved in microbial killing, vasodilation, and inhibition
(or reversal) of platelet aggregation [60]. Expression of both NOS2 and arginase in
macrophages from peritumoral AT might be indicative of a non-resolving wounding
process, which is a common feature of cancer [2].
Angiogenesis is prominent in sites of inflammation, wounding and malignancy. Several
studies have suggested an important role for IL-6 in this process. Aoki et al. showed
accelerated growth of highly vascularized tumors when IL-6-expressing NIH3T3 cells were
injected into BALB/c nu/nu mice [62]. We found a 6-fold increase in IL-6 levels in
peritumoral AT compared to control AT. By immunohistochemistry, both mononuclear and
endothelial cells were strongly positive for IL-6. This finding together with the increased
vasculature in peritumoral AT suggests that IL-6 might be a stimulator of angiogenesis in
our model. Murine sarcoma MCG101 growth and leukocyte infiltration were reduced in
IL-6 gene knockout mice and after administration of IL-6 blocking antibodies to tumor-
bearing mice [63]. Increased IL-6 expression was shown during angiogenesis accompanying
folicullogenesis and formation of the maternal decidua after embryo implantation [64]. Lin
et al. demonstrated that the absence of IL-6 interfered with angiogenesis at wound sites after
skin incisions [65]. Furthermore, Hernandez-Rodriguez et al. showed that IL-6 stimulates
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endothelial cell proliferation and differentiation into capillary-like structures in vitro as well
as full angiogenic activity in both the aortic ring (ex vivo) and chick chorioallantoic
membrane (in vivo) assays [66].
It is well known that tumors require the establishment of blood vessels to progress beyond a
few millimeters in diameter [66-69]. Initially it was believed that malignant tumor cells were
the primary source of angiogenic factors. However, it has recently been recognized that
stromal cells in tumors are also a major source for these factors. Tumor-associated pro-
inflammatory cells, in particular neutrophils and macrophages, secrete VEGF, IL-6, IL-8
and TNF-α. Our results suggest that peritumoral AT, by serving as a depot for macrophages,
forms a supportive microenvironment for tumor progression. Furthermore, peritumoral AT
is inflamed and highly angiogenic, which could provide a source of new blood vessels as
tumors expand at their periphery. The possibility to modulate recruitment and/or reorientate
macrophage polarization could theoretically slow or reverse tumor progression, especially in
tumors growing directly within AT including lymph node metastases and breast cancers.
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Fig. 1.
Reduced size of adipocytes, increased lipolysis and decreased lipid content are features of
peritumoral AT. Gross morphology examination revealed peritumoral AT as a
hypertrophied, highly vascularized, dark reddish-white mass (A, a). Peritumoral AT (n = 6)
hypertrophy revealed by increase in tissue mass in comparison to control AT (n = 6) (A, b).
Body weights of tumor-bearing mice (n = 6) in comparison to healthy controls (n = 6) (A,
c). Hematoxylin-eosin histological examination of tumor tissue (left panel), control AT
(middle panel) and peritumoral AT (right panel) revealed reduced size of adipocytes within
peritumoral AT together with increased fibrosis. Size bar, 50 μm (A, d). Similar findings
observed in breast tissues from autochthonous tumors in C3-Tag mice (A, e). Yellow arrow
heads mark adipocytes and “T” marks tumor cells. Adipocyte size distribution from control
and peritumoral AT (B, a–b). Average size of adipocytes from control (n = 1,358) and
peritumoral AT (n = 1,369) (B, c). Increased lipolysis in peritumoral AT revealed by
increased lipid spillage during AT culture (B, d–e). Oil-Red-O histological examination of
lipid content in control and peritumoral AT (n = 3) (C, a). Measurement of lipid content in
peritumoral and control AT (C, b). Data presented are mean values ± SEM. *p < 0.05; **p <
0.01; and ***p <0.001, Student’s t test
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Fig. 2.
Increased fibrosis and number of blood vessels within fibrotic areas of peritumoral AT.
Masson’s Trichrome histological examination of tumor tissue (left panel), control AT
(middle panel) and peritumoral AT (right panel) (A) at low (size bar, 200 μm) and high
magnification (size bar, 50 μm). Histological examination revealed increased number of
blood vessels within peritumoral AT restricted to fibrotic areas (A). Yellow arrow heads
clearly mark blood vessels. Quantification of Masson’s Trichrome staining (B, a).
Quantification of blood vessels within control and peritumoral AT fibrotic regions (B, b–c).
Picrosirius red histological examination of control and peritumoral AT using polarized light
microscopy. Size bar, 100 μm (C, a, left panel). Quantification of Picrosirius Red staining
(C, b). Immunohistochemical analysis of tissue sections from control and peritumoral AT
using CD31 (C, a—right panel). Total number of blood vessels within control and
peritumoral AT (C, c). Data presented are mean values ± SEM. *p < 0.05; **p < 0.01; and
***p < 0.001, Student’s t test
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Fig. 3.
Peritumoral AT is infiltrated by M2 macrophages based on surface marker expression.
Immunohistochemical analysis for the pan-leukocyte marker CD45 revealed massive
infiltration of immune cells in peritumoral AT. Size bar, 50 μm (A). Yellow arrowheads
clearly mark blood vessels. Flow cytometric analysis of the M2 macrophage marker CD301
in control and peritumoral AT. Note that 100 % of analyzed cells are CD45+ (B).
Quantification of CD11b+/CD301+ and CD11b+/CD301− cells between and within the same
control (n = 3) and peritumoral AT (n = 3) depot. Results were normalized to 0.2 g of tissue
(B). Immunohistochemical analysis for the CD301 and CD163 M2 macrophage markers in
control and peritumoral AT. Size bar, 50 μm (C, a). Fibrotic areas are marked by an
asterisk. Quantification of CD301+ and CD163+ cells between and within the same control
(n = 3) and peritumoral AT (n = 3) depot revealed accumulation of macrophages within
fibrotic areas. Data presented are mean values ± SEM. *p <0.05; **p < 0.01; and ***p <
0.001, Student’s t test
Wagner et al. Page 17
Angiogenesis. Author manuscript; available in PMC 2013 April 08.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4.
Over-expression of pro-inflammatory cytokines within peritumoral AT. Mouse cytokine
protein arrays were performed using control and peritumoral AT pooled from four mice per
group. Array analysis revealed increased expression of pro-inflammatory cytokines within
peritumoral AT (A, a). Results are in duplicate. Quantification of the mouse cytokine array
data (A, b). Immunohistochemical analysis for IL-6 reveals the presence of IL-6 positive
immune and endothelial cells in peritumoral AT. Size bar, 50 μm (B, a). The inset shows a
blood vessel stained positive for IL-6. Immunofluorescence analysis of control and
peritumoral AT shows CD11b+ macrophages co-expressing IL-6 (B, b). Increased
proliferative potential of MS1 mouse endothelial cells upon stimulation with IL-6 (B, c).
Data presented are mean values ± SEM. *p <0.05; **p < 0.01; and ***p < 0.001, Student’s t
test
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Fig. 5.
Increased angiogenic potential in peritumoral AT is associated with the presence of CD11b+
macrophages. Immunohistochemical analysis of control and peritumoral AT revealed
CD11b+ cells (yellow arrow heads) surrounding blood vessels (asterisk) exhibiting
proliferative potential (A, a). Ki-67+ cells are marked with red arrowheads. FACS sorted
CD11b+ macrophages from peritumoral AT express markers of both M1 and M2
polarization as revealed by RT-PCR (A, b). Representative examples of explants from
control or peritumoral AT after seven days in culture (B, a). Quantification of AT explants
with capillary sprouts present (n = 16, per group) (B, b). Yellow arrow heads mark vascular
structures, “ND” = none-detected. Immunohistochemical analysis of AT explants from
control and peritumoral AT revealed persistence of CD11b+ cells in highly angiogenic
peritumoral AT explants (C, a). Increased proliferative potential of MS1 mouse endothelial
cells upon stimulation with macrophage-conditioned medium using macrophages isolated
from peritumoral AT (peritumoral AT-CM), macrophages from control AT (control AT-
CM) or serum-free medium (SFM). Data presented are mean values ± SEM. *p < 0.05; **p
< 0.01; and ***p < 0.001, Student’s t test
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Fig. 6.
AT accelerates tumor growth by affecting its neovascularization. Representative photograph
of mice 14 days after B16F10 cells injection (A, a). B16F10 melanoma cells (1 × 106) were
co-injected with Matrigel into the anterior subcutaneous AT depot (white dotted line) and
dorsal midline devoid of AT (red dotted line) of C57BL6 mice. At the end of the
experiment, tumors were removed and photographed. Three tumors from AT (top) are
compared with three tumors from the dorsal midline (bottom) of the same mouse (bottom
photograph). Tumor growth is shown during the two weeks after injection (n = 6) (A, a).
Accelerated B16F10 mouse melanoma (A, b) and Lewis Lung Carcinoma (LLC) (A, d)
growth in subcutaneous AT. At sacrifice, tumors were removed and weighed. Quantification
of B16F10 (n = 6, per group) (A, c) and LLC tumor weights (A, e) (n = 6, per group).
Immunohistochemical analysis of tumor samples from fat-pad and non-fat pad using the
endothelial cell marker, CD31 (B, a). Quantification of blood vessels (B, b) and their
diameters (B, c) revealed increased numbers and diameters of blood vessels in tumors
growing in AT. Flow cytometric analysis of CD11b+ macrophages in tumors from fat-pad
and non-fat pad (B, d) shows increased numbers of positive cells in tumors grown in AT.
Data presented are mean values ± SEM. *p < 0.05; **p < 0.01; and ***p < 0.001, Student’s
t test
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